Víncula

Vincula Bio is a biotechnology company focused on developing precision medicines for immune-mediated diseases. The company leverages a proprietary platform to identify and target specific molecular nodes within the T-cell receptor (TCR) signalosome, aiming to restore immune balance rather than broadly suppressing the immune system. By focusing on the molecular drivers of T-cell dysfunction, Vincula Bio seeks to create highly selective small molecule therapies for autoimmune and inflammatory conditions. The company was launched by Westlake Village BioPartners and is currently advancing its programs through the pre-clinical stage. Led by experts in immunology and drug discovery, Vincula Bio aims to address significant unmet needs in the treatment of chronic inflammatory disorders.